Creator: Help Dementia Editorial Team
Published: 2026-04-12T01:14:25

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Patient engagement sits at the center of this dementia and brain health question.

Patient engagement strategies have become essential tools for improving retention in Alzheimer’s disease clinical trials, where dropout rates have historically threatened the viability of promising research. Data shows that the average dropout rate hovers around 30%, with some trials experiencing failure rates as high as 85% when unable to retain sufficient participants to meet statistical goals. These alarming numbers have prompted a fundamental shift in how trials are designed and managed, with forward-thinking research centers now implementing targeted engagement approaches that address the unique challenges faced by people with cognitive decline and their care partners.

The research is clear: when researchers actively engage participants through remote monitoring options, adequate compensation, study partner support, and flexible visit schedules, retention improves substantially. For example, a trial implementing a combination of eConsent, telemedicine monitoring, computerized cognitive assessments, and nurse home visits successfully reduced burden on participants while maintaining data quality—demonstrating that engagement isn’t just about keeping people in studies, but about removing unnecessary friction from their participation. The science of trial retention has evolved from assuming dropout is inevitable to understanding it as a design problem that can be solved.

Why Are Dropout Rates So High in Alzheimer’s Clinical Trials?
Understanding the Hidden Burden of Study Partner Dropout
Remote Solutions That Reduce Burden Without Sacrificing Data Quality
The Compensation Question—What Does Fair Participation Look Like?
Identifying and Supporting Participants at Highest Risk of Dropout
Recent Advances and the CTRL Roundtable Initiative
Building Retention Into Trial Design From the Start
Conclusion

Why Are Dropout Rates So High in Alzheimer’s Clinical Trials?

Alzheimer’s disease clinical trials face retention challenges that dwarf those in many other disease areas. Phase 3 trials report dropout rates of 21.2% on average, but the real problem emerges over time. Multi-year studies consistently lose 10 to 54% of their enrolled participants before completion, and here’s the critical finding: for every six-month increase in trial duration, the odds of a participant completing the study drop by 27%. This means that a two-year trial loses participants at a substantially higher rate than a one-year trial, all else being equal. The stakes are enormous. When trials fail to retain participants, they don’t just lose data—they fail to meet their statistical targets.

The consequence is that potentially effective treatments never advance toward regulatory approval, leaving future patients without access to therapies that might have helped them. Sponsors and sites must understand that retention isn’t a secondary concern; it’s foundational to whether a trial succeeds in its mission. A perfectly designed drug candidate can be lost if the trial infrastructure doesn’t keep people engaged and participating through completion. The challenge is compounded by the nature of the disease itself. People with Alzheimer’s experience cognitive decline during the trial, which can make it harder to remember appointments, understand the purpose of visits, or maintain motivation. Unlike trials for conditions where participants might feel a direct health benefit during the study, Alzheimer’s trials often show no immediate symptomatic improvement to the individual participant, making the psychological commitment required to continue participation genuinely difficult.

Why Are Dropout Rates So High in Alzheimer's Clinical Trials?

Understanding the Hidden Burden of Study Partner Dropout

A striking and often overlooked aspect of Alzheimer’s trial retention involves the study partner—the family member or caregiver who accompanies the participant to visits and provides support. research reveals that study partner dropout rates vary significantly by relationship: 35% of participants with spousal partners drop out or become unavailable, while 38% of those with adult child partners leave, and 36% with other types of partners exit before completion. When the study partner is unavailable or quits, the participant’s continued engagement becomes much harder to maintain. This represents a critical limitation in how we traditionally think about Alzheimer’s trials. The trial isn’t actually a one-person commitment—it’s a dyadic commitment requiring the sustained participation of two people over months or years.

When either member of that pair experiences burnout, illness, or a change in life circumstances, the entire enrollment collapses. A middle-aged adult child serving as study partner might face job changes, relocation, or health crises of their own. A spousal partner might become ill themselves or find the emotional burden of weekly or bi-weekly trial visits—watching their partner undergo testing for a disease they’re slowly losing—too difficult to sustain. Understanding that study partners have agency, needs, and limits is essential for designing retention strategies. Sites that recognize this have begun offering explicit support for study partners: flexible scheduling, virtual participation options, and even dedicated check-in calls to assess whether the partner is doing okay. The warning here is clear: ignoring the study partner in retention planning is a mistake that looks invisible until dropout rates spike.

Remote Solutions That Reduce Burden Without Sacrificing Data Quality

One of the most significant advances in Alzheimer’s trial retention has been the successful implementation of remote and hybrid participation models. Trials have deployed remote cognitive assessments, electronic consent (eConsent), telemedicine-based monitoring, computerized cognitive tests administered at home, nurse home visits for in-person safety assessments, and video conferencing for regular check-ins. The key insight is that these tools don’t just increase convenience—they dramatically reduce the transportation burden, which is often the single largest barrier to attendance. Consider a participant with mild-to-moderate Alzheimer’s living in a rural area 45 minutes from the trial site. Current options mean either missing visits or asking family to arrange transportation weekly. With remote cognitive assessments and telemedicine monitoring, that person can complete most study procedures from home, traveling to the site only for assessments that absolutely require in-person evaluation and safety monitoring.

Research has confirmed that participants enrolled in trials offering these remote options report lower burden and show improved completion rates. However, successful remote trial participation relies heavily on study partner engagement with the technology itself. Study partners must learn to help with device charging, remind participants to use monitoring equipment, provide emotional support when technical issues arise, and sometimes input data into digital platforms. Trials implementing remote solutions without simultaneously addressing study partner training and support see mixed results. The limitation here is that remote doesn’t automatically mean easier for everyone—older study partners may struggle with digital interfaces, and some participants lack reliable internet. Building remote solutions without considering these real-world barriers is a common mistake that undermines their potential.

Remote Solutions That Reduce Burden Without Sacrificing Data Quality

The Compensation Question—What Does Fair Participation Look Like?

Payment for trial participation sits at the intersection of ethics, recruitment success, and practical trial management. Current practice varies widely, with most sites offering compensation between $20 and $80 per visit. However, patient advisory groups and advocacy organizations have begun pushing back, arguing that these amounts fail to reflect the true value and burden of participation. These groups advocate for flat compensation rates around $200 per visit, recognizing that trial participation is work—it requires time away from employment, transportation, and cognitive and emotional energy. The comparison is instructive. A participant attending a two-hour clinic visit that takes an additional two hours to travel to and from the site has invested four hours of time. At $40 per visit, that’s $10 per hour of actual time commitment—less than minimum wage. For someone who has retired or is on disability, this might still feel worthwhile.

But for a working-age adult who is the study partner (perhaps taking time off work), the math becomes untenable. Higher compensation doesn’t solve all retention problems, but it acknowledges that asking people to participate in demanding medical research isn’t a favor—it’s a legitimate request for their time and effort. The tradeoff for sponsors is real: higher compensation increases trial costs. A multi-site trial with 200 participants attending 10 visits each (2,000 visit-events) would cost an additional $32,000 per visit-event increase ($200 vs. $168 at $80 per visit). For large Phase 3 trials, this represents millions of dollars. Yet the cost of trial failure due to poor retention often exceeds the cost of enhanced compensation. When sites have implemented higher compensation alongside other engagement strategies, retention has improved enough to make the investment worthwhile from both a scientific and financial standpoint.

Identifying and Supporting Participants at Highest Risk of Dropout

Not all participants face equal dropout risk. Research has identified specific demographic and clinical factors associated with increased likelihood of attrition: age, race, medical history, the occurrence of adverse events during the trial, the type of caregiver relationship (having a friend rather than family as the study partner is associated with higher dropout), population density (rural locations show higher dropout), and small clinical trial site staff size. Understanding these risk factors allows trials to implement targeted retention strategies rather than applying one-size-fits-all approaches. A trial site with limited staff faces a critical constraint: smaller teams have less capacity for the frequent check-ins, flexibility, and personalized support that improve retention. This is a limitation that smaller academic centers must acknowledge. A rural participant with a friend as their study partner already faces multiple risk factors—reduced population density means fewer transportation resources, and friend caregivers may lack the family obligation or commitment that keeps spousal or adult-child partners engaged.

These participants need extra support: perhaps a monthly check-in call, flexibility around visit scheduling, or even transportation assistance. A warning embedded in these findings is that dropout risk isn’t random—it clusters among vulnerable populations, which means poor retention disproportionately affects enrollment diversity. Forward-thinking trials now implement risk stratification from the baseline visit. As soon as a participant is identified as higher-risk (multiple risk factors present), the site escalates their engagement protocol. This might include assignment to a dedicated nurse coordinator, regular phone calls from the principal investigator, or offers of home visits. Early intervention prevents the slow drift toward disengagement that precedes dropout.

Identifying and Supporting Participants at Highest Risk of Dropout

Recent Advances and the CTRL Roundtable Initiative

In November 2024, the Clinical Trial Resource Library (CTRL) Roundtable convened a two-day summit titled “Advancing the Science of Recruitment for Inclusive Alzheimer’s Disease Clinical Trials.” This gathering brought together researchers, patient advocates, sponsors, and site coordinators to discuss recruitment and retention challenges and share evidence-based solutions. The focus on inclusion is significant—because historical recruitment challenges have disproportionately enrolled white, educated, well-resourced participants, limiting the generalizability of trial findings and excluding many people living with Alzheimer’s from the research process. This initiative reflects a growing recognition that patient engagement and trial retention are not just operational concerns—they’re scientific and ethical imperatives.

Improving retention directly improves statistical power and trial success rates. Improving inclusion in who we retain ensures that results apply to the full breadth of the Alzheimer’s population, not just the most accessible subgroup. As these initiatives advance, we can expect continued evolution in engagement best practices, with findings shared across the research community.

Building Retention Into Trial Design From the Start

The most successful trials in recent years have adopted what researchers call “retention by design”—building engagement strategies into the trial protocol from inception rather than attempting to troubleshoot retention problems after enrollment begins. This means decisions about visit frequency, assessment methods, remote options, compensation, and study partner support are made with retention data in mind. A trial planning for 24 months of follow-up with high-risk demographics shouldn’t replicate the visit schedule designed for a shorter, healthier population; instead, it should incorporate remote options and adjust expectations accordingly.

As the field moves forward, the integration of these evidence-based engagement strategies is becoming standard rather than exceptional. Major Alzheimer’s disease trials launched in 2025 are more likely to include remote cognitive assessments, explicit study partner support protocols, and thoughtful compensation structures than trials from five years prior. This represents genuine progress in the field’s understanding of what it takes to conduct ethical, successful research with a vulnerable population.

Conclusion

Patient engagement strategies have moved from nice-to-have features in Alzheimer’s clinical trials to essential components that determine whether research succeeds. The evidence is robust: dropout is not inevitable—it’s a response to trial design, burden, and support systems. By implementing remote options, supporting study partners, providing adequate compensation, identifying at-risk participants, and building retention considerations into trial design from the beginning, researchers can maintain enrollment and statistical power while conducting research that genuinely reflects the breadth of the Alzheimer’s population.

For people considering enrollment in an Alzheimer’s clinical trial, understanding these engagement factors is empowering. A trial that offers flexibility, remote options, and clear support for your study partner is not only more likely to retain you—it’s likely to be better designed overall. For researchers and trial sites, the message is equally clear: investment in participant engagement directly translates to scientific success.